Oncotelic Therapeutics annual ebitda
2012
2013
2014
2018
2019
2020
2021
Oncotelic Therapeutics EBITDA Growth & History (OTLC)
Oncotelic Therapeutics's calculated EBITDA was −$9.1M for fiscal 2021.
View full Oncotelic Therapeutics company overviewOncotelic Therapeutics annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2021 | 2021-12-31 | −$9.1M | −$1.8M | — |
| 2020 | 2020-12-31 | −$7.2M | −$3.0M | — |
| 2019 | 2019-12-31 | −$4.3M | −$3.6M | — |
| 2018 | 2018-12-31 | −$676,549 | $10.5M | — |
| 2014 | 2014-12-31 | −$11.1M | −$2.9M | — |
| 2013 | 2013-12-31 | −$8.3M | −$225,300 | — |
| 2012 | 2012-12-31 | −$8.0M | — | — |
Oncotelic Therapeutics quarterly ebitda
Q2.18
Q3.18
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q4 2021 | 2021-12-31 | −$1.5M | $1.6M | — |
| Q3 2021 | 2021-09-30 | −$1.8M | −$199,483 | — |
| Q2 2021 | 2021-06-30 | −$3.7M | −$3.8M | — |
| Q1 2021 | 2021-03-31 | −$2.0M | $535,115 | — |
| Q4 2020 | 2020-12-31 | −$3.1M | −$2.9M | — |
| Q3 2020 | 2020-09-30 | −$1.6M | −$1.4M | — |
| Q2 2020 | 2020-06-30 | $36,010 | — | — |
| Q1 2020 | 2020-03-31 | −$2.6M | — | — |
| Q3 2018 | 2018-09-30 | −$201,192 | — | — |
| Q2 2018 | 2018-06-30 | −$144,747 | — | — |
Oncotelic Therapeutics ebitda trends
Over the last five reported fiscal years, Oncotelic Therapeutics's ebitda decreased from −$8.3M to −$9.1M, a change of −$804,170. The latest reported quarter, Q4 2021, shows −$1.5M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Oncotelic Therapeutics filings at SEC.gov ↗